1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
   Carlos Aguado de la Rosa et al, 2022, Lung Cancer CrossRef
2. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives
   Pasquale Pisapia et al, 2017, Cancer Cytopathology CrossRef